Literature DB >> 15090727

Population-based statistics for women diagnosed with inflammatory breast cancer (United States).

Phyllis A Wingo1, Patricia M Jamison, John L Young, Paul Gargiullo.   

Abstract

OBJECTIVE: The purpose of this study was to use population-based information to describe the demographic and tumor characteristics of inflammatory breast cancer (IBC) - the most aggressive form of this disease.
METHODS: IBC cases diagnosed during 1994 through 1998 were reported to 26 population-based cancer registries covering approximately 40% of the US population. Rates were expressed per 100,000 female population and age-adjusted to the 2000 US population. Ninety-five percent gamma confidence limits were estimated for the rates.
RESULTS: Among the 3626 women diagnosed with IBC during 1994-1998, the majority were 40-59 years old. Most tumors were diagnosed at a regional (68.9%) or distant (25.3%) stage and were poorly differentiated (49.4%). The rate of IBC was 1.3 per 100,000 for all races combined. Black women had the highest risk (1.6) and Asian and Pacific Islander women the lowest (0.7).
CONCLUSIONS: IBC is an extremely rare form of breast cancer. More precise diagnostic criteria are needed to distinguish it from less aggressive forms of the disease. Future studies should use a population-based design and collect detailed clinical information, including the presence of erythema, edema or peau d'orange appearance of the skin, and other clinical signs of disease. Copyright 2004 Kluwer Academic Publishers

Entities:  

Mesh:

Year:  2004        PMID: 15090727     DOI: 10.1023/B:CACO.0000024222.61114.18

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  34 in total

1.  Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program.

Authors:  Abdi T Gudina; Glenn Copeland; Amr S Soliman; Kelly A Hirko
Journal:  Breast Cancer Res Treat       Date:  2018-11-07       Impact factor: 4.872

2.  Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells.

Authors:  Scott J Sauer; Michael Tarpley; Imran Shah; Akshay V Save; H Kim Lyerly; Steven R Patierno; Kevin P Williams; Gayathri R Devi
Journal:  Carcinogenesis       Date:  2017-03-01       Impact factor: 4.944

3.  Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.

Authors:  Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine
Journal:  J Natl Cancer Inst       Date:  2005-07-06       Impact factor: 13.506

4.  Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.

Authors:  Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; David Schottenfeld; Sofia D Merajver
Journal:  Breast Cancer Res Treat       Date:  2012-06-26       Impact factor: 4.872

Review 5.  Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.

Authors:  Tamer M Fouad; Angelica M Gutierrez Barrera; James M Reuben; Anthony Lucci; Wendy A Woodward; Michael C Stauder; Bora Lim; Sarah M DeSnyder; Banu Arun; Babiera Gildy; Vicente Valero; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Lancet Oncol       Date:  2017-04       Impact factor: 41.316

6.  Inflammatory Breast Cancer Outcomes in a Contemporary Series.

Authors:  Elizabeth Pan; Lily Tung; Omar Ragab; Elise Morocco; Julie Wecsler; Richard Sposto; Akshara Raghavendra; Eugene Chung; Julie E Lang
Journal:  Anticancer Res       Date:  2017-09       Impact factor: 2.480

7.  What can we learn from the age- and race/ethnicity- specific rates of inflammatory breast carcinoma?

Authors:  Dora Il'yasova; Sharareh Siamakpour-Reihani; Igor Akushevich; Lucy Akushevich; Neil Spector; Joellen Schildkraut
Journal:  Breast Cancer Res Treat       Date:  2011-08-18       Impact factor: 4.872

8.  Apoptosis of human carcinoma cells in the presence of potential anti-cancer drugs: III. Treatment of Colo-205 and SKBR3 cells with: cis -platin, Tamoxifen, Melphalan, Betulinic acid, L-PDMP, L-PPMP, and GD3 ganglioside.

Authors:  Subhash Basu; Rui Ma; Patrick J Boyle; Brian Mikulla; Mathew Bradley; Bradley Smith; Manju Basu; Sipra Banerjee
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

9.  Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome.

Authors:  Jennifer M Matro; Tianyu Li; Massimo Cristofanilli; Melissa E Hughes; Rebecca A Ottesen; Jane C Weeks; Yu-Ning Wong
Journal:  Clin Breast Cancer       Date:  2014-06-23       Impact factor: 3.225

10.  Locoregional treatment outcomes after multimodality management of inflammatory breast cancer.

Authors:  Ian J Bristol; Wendy A Woodward; Eric A Strom; Massimo Cristofanilli; Delora Domain; S Eva Singletary; George H Perkins; Julia L Oh; Tse-Kuan Yu; Welela Terrefe; Aysegul A Sahin; Kelly K Hunt; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-24       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.